Recent advances and perspectives in the design and development of polymyxins

Francesc Rabanal; Yolanda Cajal

doi:10.1039/c7np00023e

journal article Jan 01, 2017

Recent advances and perspectives in the design and development of polymyxins

Francesc Rabanal

Yolanda Cajal

Natural Product Reports Vol. 34 No. 7 pp. 886-908 · Royal Society of Chemistry (RSC)

View at Publisher Save 10.1039/c7np00023e

Abstract

Polymyxins: background and future perspectives. Introducing metabolism and detoxification considerations into the design of new polymyxins to reduce nephrotoxicity.

Topics

No keywords indexed for this article. Browse by subject →

References

236

[1]

Benedict J. Bacteriol. (1947)

[2]

Stansly Bull. Johns Hopkins Hosp. (1947)

[3]

Ainsworth Nature (1947) 10.1038/160263a0

[4]

Orwa J. Chromatogr. A (2001) 10.1016/s0021-9673(01)00585-4

[5]

Decolin J. Chromatogr. Sci. (1997) 10.1093/chromsci/35.12.557

[6]

Orwa J. Antibiot. (2001) 10.7164/antibiotics.54.595

[7]

He J. Antimicrob. Chemother. (2013) 10.1093/jac/dks536

[8]

Falagas Int. J. Antimicrob. Agents (2005) 10.1016/j.ijantimicag.2005.09.004

[9]

Gilbert Clin. Infect. Dis. (2010) 10.1086/652237

[10]

CDC webpage, https://www.cdc.gov/drugresistance/about.html

[11]

F. Rabanal and Y.Cajal, in New Weapons to Control Bacterial Growth, ed. T. G. Villa and M. Viñas, Springer International Publishing, Switzerland, 2016, pp. 433–452

[12]

Sierra Expert Opin. Biol. Ther. (2017) 10.1080/14712598.2017.1315402

[13]

WHO press release, http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/

[14]

Velkov J. Med. Chem. (2010) 10.1021/jm900999h

[15]

Pharmacology of Polymyxins: New Insights into an ‘Old‘ Class of Antibiotics

Tony Velkov, Kade D Roberts, Roger L Nation et al.

Future Microbiology 2013 10.2217/fmb.13.39

[16]

Vaara J. Antimicrob. Chemother. (2013) 10.1093/jac/dkt039

[17]

Brown J. Antibiot. (2017) 10.1038/ja.2016.146

[18]

Raza J. Plant Pathol. (2008)

[19]

Brownlee Br. J. Pharmacol. (1952)

[20]

Koyama J. Antibiot., Ser. B (1950)

[21]

K. Hayashi and T. Suzuki, Kyoto University Research information Repository, 1965, http://repository.kulib.kyoto-u.ac.jp/dspace/bitstream/2433/76067/1/chd043_3_259.pdf

[22]

Polymyxin and Related Peptide Antibiotics

D R Storm, K S Rosenthal, P E Swanson

Annual Review of Biochemistry 1977 10.1146/annurev.bi.46.070177.003451

[23]

Martin J. Biol. Chem. (2003) 10.1074/jbc.m212364200

[24]

Niu BMC Microbiol. (2013) 10.1186/1471-2180-13-137

[25]

Kimura J. Antibiot. (1969) 10.7164/antibiotics.22.449

[26]

Shoji J. Antibiot. (1977) 10.7164/antibiotics.30.1029

[27]

Shoji J. Antibiot. (1977) 10.7164/antibiotics.30.1035

[28]

Shoji J. Antibiot. (1977) 10.7164/antibiotics.30.1042

[29]

Shoji J. Antibiot. (1977) 10.7164/antibiotics.30.427

[30]

Parker J. Antibiot. (1977) 10.7164/antibiotics.30.767

[31]

Terabe J. Chromatogr. (1979) 10.1016/s0021-9673(00)92299-4

[32]

Cochrane Med. Res. Rev. (2016) 10.1002/med.21321

[33]

Shaheen Chem. Biol. (2011) 10.1016/j.chembiol.2011.09.017

[34]

Velkov Nat. Prod. Rep. (2017) 10.1039/c6np00113k

[35]

Falagas Clin. Infect. Dis. (2005) 10.1086/429323

[36]

Mogi J. Biochem. (2009) 10.1093/jb/mvp096

[37]

Rastogi Ann. Inst. Pasteur/Microbiol. (1986) 10.1016/s0769-2609(86)80004-7

[38]

Zhai Int. J. Antimicrob. Agents (2013) 10.1016/j.ijantimicag.2012.11.006

[39]

He Int. J. Antimicrob. Agents (2010) 10.1016/j.ijantimicag.2009.11.005

[40]

Tam Antimicrob. Agents Chemother. (2011) 10.1128/aac.00119-11

[41]

Roberts ACS Infect. Dis. (2015) 10.1021/acsinfecdis.5b00085

[42]

Kassamali Antimicrob. Agents Chemother. (2015) 10.1128/aac.01021-15

[43]

Manchandani Antimicrob. Agents Chemother. (2016) 10.1128/aac.00702-16

[44]

Sivanesan J. Nat. Prod. (2017) 10.1021/acs.jnatprod.6b01176

[45]

Abdelraouf Antimicrob. Agents Chemother. (2012) 10.1128/aac.01333-12

[46]

M. E. Falagas and K. Z.Vardakas, http://www.antimicrobe.org/d05.asp

[47]

Barnett Br. J. Pharmacol.Chemother. (1964) 10.1111/j.1476-5381.1964.tb01610.x

[48]

Li J. Antimicrob. Chemother. (2004) 10.1093/jac/dkh167

[49]

Bergen Antimicrob. Agents Chemother. (2006) 10.1128/aac.00035-06

[50]

Li Antimicrob. Agents Chemother. (2003) 10.1128/aac.47.4.1364-1370.2003

Showing 50 of 236 references

Cited By

134

Repurposing a neurodegenerative disease drug to treat Gram-negative antibiotic-resistant bacterial sepsis

David M. P. De Oliveira, Lisa Bohlmann · 2020

Science Translational Medicine

Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining

Zheng Zhong, Wei-Peng Zhang · 2018

Nature Communications

Metrics

134

Citations

236

References

Details

Published: Jan 01, 2017
Vol/Issue: 34(7)
Pages: 886-908

Authors

F

Francesc Rabanal

Organic Chemistry Section; Department of Inorganic and Organic Chemistry; Faculty of Chemistry; University of Barcelona; Spain

Y

Yolanda Cajal

Department of Pharmacy; Pharmaceutical Technology and Physical Chemistry; Faculty of Pharmacy and Food Sciences; University of Barcelona; Spain

Cite This Article

Francesc Rabanal, Yolanda Cajal (2017). Recent advances and perspectives in the design and development of polymyxins. Natural Product Reports, 34(7), 886-908. https://doi.org/10.1039/c7np00023e

Recent advances and perspectives in the design and development of polymyxins

You May Also Like